{
    "id": 50921,
    "name": "pharynx squamous cell carcinoma",
    "source": "DOID",
    "definition": "A pharynx cancer that has_material_basis_in squamous cells. [url:http\\://en.wikipedia.org/wiki/Squamous-cell_carcinoma]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0050921",
    "evidence": [
        {
            "id": 9145,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RN927C demonstrated cytotoxicity in a Tacstd2 (Trop-2)-expressing pharynx squamous cell carcinoma cell line in culture (PMID: 27582525).",
            "molecularProfile": {
                "id": 26744,
                "profileName": "TACSTD2 positive"
            },
            "therapy": {
                "id": 4913,
                "therapyName": "RN927C",
                "synonyms": null
            },
            "indication": {
                "id": 50921,
                "name": "pharynx squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6932,
                    "pubMedId": 27582525,
                    "title": "RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27582525"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10017,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6738 treatment increased sensitivity to radiotherapy in a pharynx squamous cell carcinoma cell line harboring a TP53 mutation in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 28062704).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 5346,
                "therapyName": "AZD6738 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 50921,
                "name": "pharynx squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7909,
                    "pubMedId": 28062704,
                    "title": "Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28062704"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT03247309",
            "title": "TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) (ACTengine)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7285,
                    "therapyName": "Aldesleukin + IMA201",
                    "synonyms": null
                },
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03258008",
            "title": "Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6148,
                    "therapyName": "ISA101b + Utomilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03383094",
            "title": "Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 6559,
                    "therapyName": "Cisplatin + Radiotherapy",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03601507",
            "title": "Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 691,
                    "therapyName": "Alpelisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03618134",
            "title": "Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03719690",
            "title": "Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 938,
                    "therapyName": "Tipifarnib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03906526",
            "title": "A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3091,
                    "therapyName": "Motolimod",
                    "synonyms": null
                },
                {
                    "id": 8774,
                    "therapyName": "Motolimod + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03944915",
            "title": "De-Escalation Therapy for Human Papillomavirus Negative Disease (DEPEND)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5303,
                    "therapyName": "Carboplatin + Nivolumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 8378,
                    "therapyName": "Cisplatin + Filgrastim + Fluorouracil + Hydroxyurea + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04106362",
            "title": "Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 1915,
                    "therapyName": "Cetuximab + Cisplatin",
                    "synonyms": null
                }
            ]
        }
    ]
}